186 related articles for article (PubMed ID: 23881989)
21. A genomic instability score in discriminating nonequivalent outcomes of BRCA1/2 mutations and in predicting outcomes of ovarian cancer treated with platinum-based chemotherapy.
Zhang S; Yuan Y; Hao D
PLoS One; 2014; 9(12):e113169. PubMed ID: 25437005
[TBL] [Abstract][Full Text] [Related]
22. Genetics of breast cancer: a topic in evolution.
Shiovitz S; Korde LA
Ann Oncol; 2015 Jul; 26(7):1291-9. PubMed ID: 25605744
[TBL] [Abstract][Full Text] [Related]
23. Hereditary breast cancer: clinical, pathological and molecular characteristics.
Larsen MJ; Thomassen M; Gerdes AM; Kruse TA
Breast Cancer (Auckl); 2014; 8():145-55. PubMed ID: 25368521
[TBL] [Abstract][Full Text] [Related]
24. Histone deacetylase inhibitor treatment induces 'BRCAness' and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells.
Ha K; Fiskus W; Choi DS; Bhaskara S; Cerchietti L; Devaraj SG; Shah B; Sharma S; Chang JC; Melnick AM; Hiebert S; Bhalla KN
Oncotarget; 2014 Jul; 5(14):5637-50. PubMed ID: 25026298
[TBL] [Abstract][Full Text] [Related]
25. 'BRCAness' and its implications for platinum action in gynecologic cancer.
Muggia F; Safra T
Anticancer Res; 2014 Feb; 34(2):551-6. PubMed ID: 24510983
[TBL] [Abstract][Full Text] [Related]
26. Doubling down on the PI3K-AKT-mTOR pathway enhances the antitumor efficacy of PARP inhibitor in triple negative breast cancer model beyond BRCA-ness.
De P; Sun Y; Carlson JH; Friedman LS; Leyland-Jones BR; Dey N
Neoplasia; 2014 Jan; 16(1):43-72. PubMed ID: 24563619
[TBL] [Abstract][Full Text] [Related]
27. PARP inhibitors in ovarian cancer: current status and future promise.
Liu JF; Konstantinopoulos PA; Matulonis UA
Gynecol Oncol; 2014 May; 133(2):362-9. PubMed ID: 24607283
[TBL] [Abstract][Full Text] [Related]
28. BRCAness revisited.
Lord CJ; Ashworth A
Nat Rev Cancer; 2016 Feb; 16(2):110-20. PubMed ID: 26775620
[TBL] [Abstract][Full Text] [Related]
29. Association of BRCA1/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes.
Timms KM; Abkevich V; Hughes E; Neff C; Reid J; Morris B; Kalva S; Potter J; Tran TV; Chen J; Iliev D; Sangale Z; Tikishvili E; Perry M; Zharkikh A; Gutin A; Lanchbury JS
Breast Cancer Res; 2014 Dec; 16(6):475. PubMed ID: 25475740
[TBL] [Abstract][Full Text] [Related]
30. Beyond Breast and Ovarian Cancers: PARP Inhibitors for BRCA Mutation-Associated and BRCA-Like Solid Tumors.
O'Sullivan CC; Moon DH; Kohn EC; Lee JM
Front Oncol; 2014; 4():42. PubMed ID: 24616882
[TBL] [Abstract][Full Text] [Related]
31. PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies.
Lee JM; Ledermann JA; Kohn EC
Ann Oncol; 2014 Jan; 25(1):32-40. PubMed ID: 24225019
[TBL] [Abstract][Full Text] [Related]
32. Targeting triple-negative breast cancer and high-grade ovarian carcinoma: refining BRCAness beyond BRCA1/2 mutations?
Jacot W; Theillet C; Guiu S; Lamy PJ
Future Oncol; 2015; 11(4):557-9. PubMed ID: 25686112
[No Abstract] [Full Text] [Related]
33. Novel treatment strategies in triple-negative breast cancer: specific role of poly(adenosine diphosphate-ribose) polymerase inhibition.
Audeh MW
Pharmgenomics Pers Med; 2014; 7():307-16. PubMed ID: 25342917
[TBL] [Abstract][Full Text] [Related]
34. Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers.
Watkins JA; Irshad S; Grigoriadis A; Tutt AN
Breast Cancer Res; 2014 Jun; 16(3):211. PubMed ID: 25093514
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of poly(ADP-ribosyl)ation in cancer: old and new paradigms revisited.
Lupo B; Trusolino L
Biochim Biophys Acta; 2014 Aug; 1846(1):201-15. PubMed ID: 25026313
[TBL] [Abstract][Full Text] [Related]
36. 53BP1, BRCA1, and the choice between recombination and end joining at DNA double-strand breaks.
Daley JM; Sung P
Mol Cell Biol; 2014 Apr; 34(8):1380-8. PubMed ID: 24469398
[TBL] [Abstract][Full Text] [Related]
37. DNA DSB repair pathway choice: an orchestrated handover mechanism.
Kakarougkas A; Jeggo PA
Br J Radiol; 2014 Mar; 87(1035):20130685. PubMed ID: 24363387
[TBL] [Abstract][Full Text] [Related]
38. A comprehensive focus on global spectrum of BRCA1 and BRCA2 mutations in breast cancer.
Karami F; Mehdipour P
Biomed Res Int; 2013; 2013():928562. PubMed ID: 24312913
[TBL] [Abstract][Full Text] [Related]
39. Molecular pathways: how can BRCA-mutated tumors become resistant to PARP inhibitors?
Bouwman P; Jonkers J
Clin Cancer Res; 2014 Feb; 20(3):540-7. PubMed ID: 24270682
[TBL] [Abstract][Full Text] [Related]
40. Mechanisms of resistance to therapies targeting BRCA-mutant cancers.
Lord CJ; Ashworth A
Nat Med; 2013 Nov; 19(11):1381-8. PubMed ID: 24202391
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
